204 related articles for article (PubMed ID: 22619516)
1. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage.
Shi NQ; Gao W; Xiang B; Qi XR
Int J Nanomedicine; 2012; 7():1613-21. PubMed ID: 22619516
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
J Nucl Med; 2011 Feb; 52(2):279-86. PubMed ID: 21233187
[TBL] [Abstract][Full Text] [Related]
3. Protease-Activable Cell-Penetrating Peptide-Protoporphyrin Conjugate for Targeted Photodynamic Therapy in Vivo.
Li SY; Cheng H; Qiu WX; Liu LH; Chen S; Hu Y; Xie BR; Li B; Zhang XZ
ACS Appl Mater Interfaces; 2015 Dec; 7(51):28319-29. PubMed ID: 26634784
[TBL] [Abstract][Full Text] [Related]
4. In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Contrast Media Mol Imaging; 2015; 10(1):59-66. PubMed ID: 24823643
[TBL] [Abstract][Full Text] [Related]
5. Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery.
Cheng H; Zhu JY; Xu XD; Qiu WX; Lei Q; Han K; Cheng YJ; Zhang XZ
ACS Appl Mater Interfaces; 2015 Jul; 7(29):16061-9. PubMed ID: 26161578
[TBL] [Abstract][Full Text] [Related]
6. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
7. Taming the Wildness of "Trojan-Horse" Peptides by Charge-Guided Masking and Protease-Triggered Demasking for the Controlled Delivery of Antitumor Agents.
Shi NQ; Qi XR
ACS Appl Mater Interfaces; 2017 Mar; 9(12):10519-10529. PubMed ID: 28290666
[TBL] [Abstract][Full Text] [Related]
8. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
9. Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2/9 activatable peptide probes.
van Duijnhoven SM; Robillard MS; Hermann S; Kuhlmann MT; Schäfers M; Nicolay K; Grüll H
Mol Pharm; 2014 May; 11(5):1415-23. PubMed ID: 24641497
[TBL] [Abstract][Full Text] [Related]
10. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
Ryu JS; Kratz F; Raucher D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
You Y; Xu Z; Chen Y
Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
[TBL] [Abstract][Full Text] [Related]
13. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
14. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
[TBL] [Abstract][Full Text] [Related]
15. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides.
Aguilera TA; Olson ES; Timmers MM; Jiang T; Tsien RY
Integr Biol (Camb); 2009 Jun; 1(5-6):371-81. PubMed ID: 20023744
[TBL] [Abstract][Full Text] [Related]
16. Protease-activatable cell-penetrating peptide possessing ROS-triggered phase transition for enhanced cancer therapy.
Yoo J; Sanoj Rejinold N; Lee D; Jon S; Kim YC
J Control Release; 2017 Oct; 264():89-101. PubMed ID: 28842316
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.
Darwish S; Sadeghiani N; Fong S; Mozaffari S; Hamidi P; Withana T; Yang S; Tiwari RK; Parang K
Eur J Med Chem; 2019 Jan; 161():594-606. PubMed ID: 30396106
[TBL] [Abstract][Full Text] [Related]
18. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells.
Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F
Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.
Du Y; Lin X; Feng Q; Pan X; Song S; Yang J
Anticancer Drugs; 2022 Jan; 33(1):e562-e572. PubMed ID: 34338241
[TBL] [Abstract][Full Text] [Related]
20. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin.
Lee GY; Park K; Kim SY; Byun Y
Eur J Pharm Biopharm; 2007 Nov; 67(3):646-54. PubMed ID: 17499491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
